248,483 Shares in PROCEPT BioRobotics Corporation $PRCT Acquired by Deutsche Bank AG

Deutsche Bank AG purchased a new position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 248,483 shares of the company's stock, valued at approximately $5,611,000. Deutsche Bank AG owned about 0.44% of PROCEPT BioRobotics at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. AQR Capital Management LLC lifted its stake in shares of PROCEPT BioRobotics by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company's stock worth $1,101,000 after purchasing an additional 1,286 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in PROCEPT BioRobotics by 9.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company's stock valued at $8,923,000 after buying an additional 13,767 shares during the period. Intech Investment Management LLC grew its position in PROCEPT BioRobotics by 54.4% during the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company's stock valued at $1,654,000 after buying an additional 10,002 shares during the period. Prudential Financial Inc. increased its holdings in PROCEPT BioRobotics by 100.4% during the second quarter. Prudential Financial Inc. now owns 6,815 shares of the company's stock valued at $393,000 after buying an additional 3,415 shares during the last quarter. Finally, State Street Corp increased its holdings in PROCEPT BioRobotics by 6.9% during the second quarter. State Street Corp now owns 1,269,110 shares of the company's stock valued at $73,101,000 after buying an additional 81,849 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Larry L. Wood purchased 23,900 shares of the firm's stock in a transaction dated Friday, August 7th. The stock was purchased at an average price of $20.85 per share, with a total value of $498,315.00. Following the completion of the purchase, the chief executive officer owned 23,900 shares of the company's stock, valued at approximately $498,315. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. In the last three months, insiders have sold 1,000 shares of company stock worth $28,480. Company insiders own 4.00% of the company's stock.

PROCEPT BioRobotics News Roundup

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: The lawsuit covers investors who purchased PROCEPT shares from February 28, 2024, through February 25, 2026. Investors may apply to serve as lead plaintiff, while any potential recovery would be handled through a contingency-fee arrangement. DJS Law Group lawsuit notice
• Negative Sentiment: The complaints allege PROCEPT misled investors about sales performance and inventory conditions, including weaker-than-expected unit handpiece sales, excess customer inventory, channel stuffing, and late-quarter bulk discounts. These allegations have not been proven in court but could raise litigation costs, create potential liabilities, and damage investor confidence. Hagens Berman investor alert
• Negative Sentiment: Kahn Swick & Foti said the alleged inventory issues contributed to an approximately 18% share-price decline during the relevant period. The repeated notices from Rosen, Kaplan Fox, SBS, Levi & Korsinsky, and other firms reinforce the negative legal narrative surrounding PROCEPT. Kahn Swick & Foti lawsuit notice

Wall Street Analyst Weigh In

Several research firms recently weighed in on PRCT. Leerink Partners downgraded PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $31.00 to $29.00 in a research report on Thursday, June 11th. Wells Fargo & Company downgraded PROCEPT BioRobotics from an "overweight" rating to an "equal weight" rating and set a $19.00 price objective on the stock. in a research note on Wednesday, August 5th. Robert W. Baird set a $20.00 price objective on PROCEPT BioRobotics in a research report on Wednesday, August 5th. William Blair cut PROCEPT BioRobotics from an "outperform" rating to a "market perform" rating in a research report on Wednesday, August 5th. Finally, Truist Financial set a $21.00 price objective on PROCEPT BioRobotics in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $28.00.

PROCEPT BioRobotics Stock Down 2.0%

PRCT opened at $21.25 on Tuesday. The company has a market capitalization of $1.22 billion, a PE ratio of -10.95 and a beta of 0.89. The firm has a 50-day simple moving average of $20.37 and a two-hundred day simple moving average of $24.11. The company has a quick ratio of 5.35, a current ratio of 6.55 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics Corporation has a 52 week low of $16.67 and a 52 week high of $42.43.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 30.62% and a negative net margin of 32.53%.The business had revenue of $94.50 million during the quarter, compared to the consensus estimate of $92.77 million. During the same quarter in the prior year, the firm posted ($0.35) EPS. The company's revenue for the quarter was up 19.3% on a year-over-year basis. Analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 earnings per share for the current fiscal year.

About PROCEPT BioRobotics

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company's technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company's flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source